Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 10;35(20):2240-2250.
doi: 10.1200/JCO.2016.69.4935. Epub 2017 Apr 27.

Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores

Julie Lecarpentier  1 , Valentina Silvestri  1 , Karoline B Kuchenbaecker  1 , Daniel Barrowdale  1 , Joe Dennis  1 , Lesley McGuffog  1 , Penny Soucy  1 , Goska Leslie  1 , Piera Rizzolo  1 , Anna Sara Navazio  1 , Virginia Valentini  1 , Veronica Zelli  1 , Andrew Lee  1 , Ali Amin Al Olama  1 , Jonathan P Tyrer  1 , Melissa Southey  1 , Esther M John  1 , Thomas A Conner  1 , David E Goldgar  1 , Saundra S Buys  1 , Ramunas Janavicius  1 , Linda Steele  1 , Yuan Chun Ding  1 , Susan L Neuhausen  1 , Thomas V O Hansen  1 , Ana Osorio  1 , Jeffrey N Weitzel  1 , Angela Toss  1 , Veronica Medici  1 , Laura Cortesi  1 , Ines Zanna  1 , Domenico Palli  1 , Paolo Radice  1 , Siranoush Manoukian  1 , Bernard Peissel  1 , Jacopo Azzollini  1 , Alessandra Viel  1 , Giulia Cini  1 , Giuseppe Damante  1 , Stefania Tommasi  1 , Paolo Peterlongo  1 , Florentia Fostira  1 , Ute Hamann  1 , D Gareth Evans  1 , Alex Henderson  1 , Carole Brewer  1 , Diana Eccles  1 , Jackie Cook  1 , Kai-Ren Ong  1 , Lisa Walker  1 , Lucy E Side  1 , Mary E Porteous  1 , Rosemarie Davidson  1 , Shirley Hodgson  1 , Debra Frost  1 , Julian Adlard  1 , Louise Izatt  1 , Ros Eeles  1 , Steve Ellis  1 , Marc Tischkowitz  1 ; EMBRACE; Andrew K Godwin  1 , Alfons Meindl  1 , Andrea Gehrig  1 , Bernd Dworniczak  1 , Christian Sutter  1 , Christoph Engel  1 , Dieter Niederacher  1 , Doris Steinemann  1 , Eric Hahnen  1 , Jan Hauke  1 , Kerstin Rhiem  1 , Karin Kast  1 , Norbert Arnold  1 , Nina Ditsch  1 , Shan Wang-Gohrke  1 , Barbara Wappenschmidt  1 , Dorothea Wand  1 , Christine Lasset  1 , Dominique Stoppa-Lyonnet  1 , Muriel Belotti  1 , Francesca Damiola  1 , Laure Barjhoux  1 , Sylvie Mazoyer  1 ; GEMO Study Collaborators; Mattias Van Heetvelde  1 , Bruce Poppe  1 , Kim De Leeneer  1 , Kathleen B M Claes  1 , Miguel de la Hoya  1 , Vanesa Garcia-Barberan  1 , Trinidad Caldes  1 , Pedro Perez Segura  1 , Johanna I Kiiski  1 , Kristiina Aittomäki  1 , Sofia Khan  1 , Heli Nevanlinna  1 , Christi J van Asperen  1 ; HEBON; Tibor Vaszko  1 , Miklos Kasler  1 , Edith Olah  1 , Judith Balmaña  1 , Sara Gutiérrez-Enríquez  1 , Orland Diez  1 , Alex Teulé  1 , Angel Izquierdo  1 , Esther Darder  1 , Joan Brunet  1 , Jesús Del Valle  1 , Lidia Feliubadalo  1 , Miquel Angel Pujana  1 , Conxi Lazaro  1 , Adalgeir Arason  1 , Bjarni A Agnarsson  1 , Oskar Th Johannsson  1 , Rosa B Barkardottir  1 , Elisa Alducci  1 , Silvia Tognazzo  1 , Marco Montagna  1 , Manuel R Teixeira  1 , Pedro Pinto  1 , Amanda B Spurdle  1 , Helene Holland  1 ; KConFab Investigators; Jong Won Lee  1 , Min Hyuk Lee  1 , Jihyoun Lee  1 , Sung-Won Kim  1 , Eunyoung Kang  1 , Zisun Kim  1 , Priyanka Sharma  1 , Timothy R Rebbeck  1 , Joseph Vijai  1 , Mark Robson  1 , Anne Lincoln  1 , Jacob Musinsky  1 , Pragna Gaddam  1 , Yen Y Tan  1 , Andreas Berger  1 , Christian F Singer  1 , Jennifer T Loud  1 , Mark H Greene  1 , Anna Marie Mulligan  1 , Gord Glendon  1 , Irene L Andrulis  1 , Amanda Ewart Toland  1 , Leigha Senter  1 , Anders Bojesen  1 , Henriette Roed Nielsen  1 , Anne-Bine Skytte  1 , Lone Sunde  1 , Uffe Birk Jensen  1 , Inge Sokilde Pedersen  1 , Lotte Krogh  1 , Torben A Kruse  1 , Maria A Caligo  1 , Sook-Yee Yoon  1 , Soo-Hwang Teo  1 , Anna von Wachenfeldt  1 , Dezheng Huo  1 , Sarah M Nielsen  1 , Olufunmilayo I Olopade  1 , Katherine L Nathanson  1 , Susan M Domchek  1 , Christa Lorenchick  1 , Rachel C Jankowitz  1 , Ian Campbell  1 , Paul James  1 , Gillian Mitchell  1 , Nick Orr  1 , Sue Kyung Park  1 , Mads Thomassen  1 , Kenneth Offit  1 , Fergus J Couch  1 , Jacques Simard  1 , Douglas F Easton  1 , Georgia Chenevix-Trench  1 , Rita K Schmutzler  1 , Antonis C Antoniou  1 , Laura Ottini  1
Affiliations

Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores

Julie Lecarpentier et al. J Clin Oncol. .

Abstract

Purpose BRCA1/2 mutations increase the risk of breast and prostate cancer in men. Common genetic variants modify cancer risks for female carriers of BRCA1/2 mutations. We investigated-for the first time to our knowledge-associations of common genetic variants with breast and prostate cancer risks for male carriers of BRCA1/ 2 mutations and implications for cancer risk prediction. Materials and Methods We genotyped 1,802 male carriers of BRCA1/2 mutations from the Consortium of Investigators of Modifiers of BRCA1/2 by using the custom Illumina OncoArray. We investigated the combined effects of established breast and prostate cancer susceptibility variants on cancer risks for male carriers of BRCA1/2 mutations by constructing weighted polygenic risk scores (PRSs) using published effect estimates as weights. Results In male carriers of BRCA1/2 mutations, PRS that was based on 88 female breast cancer susceptibility variants was associated with breast cancer risk (odds ratio per standard deviation of PRS, 1.36; 95% CI, 1.19 to 1.56; P = 8.6 × 10-6). Similarly, PRS that was based on 103 prostate cancer susceptibility variants was associated with prostate cancer risk (odds ratio per SD of PRS, 1.56; 95% CI, 1.35 to 1.81; P = 3.2 × 10-9). Large differences in absolute cancer risks were observed at the extremes of the PRS distribution. For example, prostate cancer risk by age 80 years at the 5th and 95th percentiles of the PRS varies from 7% to 26% for carriers of BRCA1 mutations and from 19% to 61% for carriers of BRCA2 mutations, respectively. Conclusion PRSs may provide informative cancer risk stratification for male carriers of BRCA1/2 mutations that might enable these men and their physicians to make informed decisions on the type and timing of breast and prostate cancer risk management.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Predicted breast cancer cumulative risk for male carriers of BRCA2 mutations by percentile of overall polygenic risk score that was constructed by using results from population-based studies.
Fig 2.
Fig 2.
Predicted prostate cancer cumulative risk for male carriers of BRCA1 mutations by percentiles of prostate cancer polygenic risk score that was constructed by using results from population-based studies.
Fig 3.
Fig 3.
Predicted prostate cancer cumulative risk for male carriers of BRCA2 mutations by percentiles of prostate cancer polygenic risk score that was constructed by using results from population-based studies.
See this image and copyright information in PMC

Comment in

Similar articles

  • Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
    Barnes DR, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arason A, Arnold N, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Belotti M, Benitez J, Berthet P, Boonen SE, Borg Å, Bozsik A, Brady AF, Brennan P, Brewer C, Brunet J, Bucalo A, Buys SS, Caldés T, Caligo MA, Campbell I, Cassingham H, Christensen LL, Cini G, Claes KBM; GEMO Study Collaborators; EMBRACE Collaborators; Cook J, Coppa A, Cortesi L, Damante G, Darder E, Davidson R, de la Hoya M, De Leeneer K, de Putter R, Del Valle J, Diez O, Ding YC, Domchek SM, Donaldson A, Eason J, Eeles R, Engel C, Evans DG, Feliubadaló L, Fostira F, Frone M, Frost D, Gallagher D, Gehrig A, Giraud S, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gregory H, Gross E, Hahnen E, Hamann U, Hansen TVO, Hanson H, Hentschel J, Horvath J; KConFab Investigators; HEBON Investigators; Izatt L, Izquierdo A, James PA, Janavicius R, Jensen UB, Johannsson OT, John EM, Kramer G, Kroeldrup L, Kruse TA, Lautrup C, Lazaro C, Lesueur F, Lopez-Fernández A, Mai PL, Manoukian S, Matrai Z, Matricardi L, Maxwell KN, Mebirouk N, Meindl A, Montagna M, Monteiro AN, Morrison PJ, … See abstract for full author list ➔ Barnes DR, et al. J Natl Cancer Inst. 2022 Jan 11;114(1):109-122. doi: 10.1093/jnci/djab147. J Natl Cancer Inst. 2022. PMID: 34320204 Free PMC article.
  • Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
    Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J, Domchek SM, Robson M, Spurdle AB, Ramus SJ, Mavaddat N, Terry MB, Neuhausen SL, Schmutzler RK, Simard J, Pharoah PDP, Offit K, Couch FJ, Chenevix-Trench G, Easton DF, Antoniou AC. Kuchenbaecker KB, et al. J Natl Cancer Inst. 2017 Jul 1;109(7):djw302. doi: 10.1093/jnci/djw302. J Natl Cancer Inst. 2017. PMID: 28376175 Free PMC article.
  • Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.
    Roed Nielsen H, Petersen J, Therkildsen C, Skytte AB, Nilbert M. Roed Nielsen H, et al. Acta Oncol. 2016;55(1):38-44. doi: 10.3109/0284186X.2015.1067714. Epub 2015 Sep 11. Acta Oncol. 2016. PMID: 26360800
  • Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.
    Milne RL, Antoniou AC. Milne RL, et al. Ann Oncol. 2011 Jan;22 Suppl 1:i11-7. doi: 10.1093/annonc/mdq660. Ann Oncol. 2011. PMID: 21285145 Review.
  • Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.
    Liede A, Karlan BY, Narod SA. Liede A, et al. J Clin Oncol. 2004 Feb 15;22(4):735-42. doi: 10.1200/JCO.2004.05.055. J Clin Oncol. 2004. PMID: 14966099 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl. 2012;14:409–414. - PMC - PubMed
    1. Rizzolo P, Silvestri V, Tommasi S, et al. Male breast cancer: Genetics, epigenetics, and ethical aspects. Ann Oncol. 2013;24(suppl 8):viii75–viii82. - PubMed
    1. Kote-Jarai Z, Leongamornlert D, Saunders E, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: Implications for genetic testing in prostate cancer patients. Br J Cancer. 2011;105:1230–1234. - PMC - PubMed
    1. Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 2012;106:1697–1701. - PMC - PubMed
    1. Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res. 2002;4:R2. - PMC - PubMed